14293-44-8
Chemical Structure
Xipamide
- CAS No.: 14293-44-8
- Formula:C15H15ClN2O4S
- Molecular Weight:354.81
IUPAC Name: 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide
InChIKey: MTZBBNMLMNBNJL-UHFFFAOYSA-N
SMILES: O=C(NC1=C(C)C=CC=C1C)C2=CC(S(=O)(N)=O)=C(Cl)C=C2O
Biological Activity: Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium cotransporter inhibitor, with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, promoting potassium and magnesium excretion while increasing calcium reabsorption. Xipamide is cleared primarily via the renal route and causes a transient decrease in glomerular filtration rate under specific conditions. Xipamide can be applied in research related to cardiovascular diseases, hypertension, advanced renal failure, and cirrhosis with ascites[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Xipamide | 99.74% | Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium cotransporter inhibitor, with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, promoting potassium and magnesium excretion while increasing calcium reabsorption. Xipamide is cleared primarily via the renal route and causes a transient decrease in glomerular filtration rate under specific conditions. Xipamide can be applied in research related to cardiovascular diseases, hypertension, advanced renal failure, and cirrhosis with ascites. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xipamide (Standard) | ≥98% | Xipamide (Standard) is the analytical standard of Xipamide (HY-W042301). This product is intended for research and analytical applications. Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium cotransporter inhibitor, with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, promoting potassium and magnesium excretion while increasing calcium reabsorption. Xipamide is cleared primarily via the renal route and causes a transient decrease in glomerular filtration rate under specific conditions. Xipamide can be applied in research related to cardiovascular diseases, hypertension, advanced renal failure, and cirrhosis with ascites. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xipamide-d6 | Xipamide-d6 is the deuterated-labeled Xipamide (HY-W042301). Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na+/Cl--potassium cotransporter inhibitor, with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl-/NaCO3- anion exchanger, promoting potassium and magnesium excretion while increasing calcium reabsorption. Xipamide is cleared primarily via the renal route and causes a transient decrease in glomerular filtration rate under specific conditions. Xipamide can be applied in research related to cardiovascular diseases, hypertension, advanced renal failure, and cirrhosis with ascites. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.65
HY-114542LY 201409 -
Similarity Score 0.63
HY-B0135Furosemide -
Similarity Score 0.63
HY-B1040Ftaxilide -
Similarity Score 0.62
HY-114705Ameltolide -
Similarity Score 0.62
HY-178751Z116334910 -
Similarity Score 0.61
HY-B0135ARFurosemide sodium (Standard) -
Similarity Score 0.61
HY-B0209RMetolazone (Standard) -
Similarity Score 0.60
HY-182307OH14 -
Similarity Score 0.60
HY-117971BVT173187 -
Explore the MedChemAI to find more analogs
References
- [1]. Taouil K, et al. Inhibition by xipamide of amiloride-induced acidification in cultured rat cardiocytes. Eur J Pharmacol. 1997;324(2-3):289-294. [Content Brief]
- [2]. Nazaret C, et al. Inhibition of the Cl-/NaCO3-anion exchanger by xipamide in human red blood cells[J]. European journal of pharmacology, 1987, 144(3): 353-362.
